A_comparative_trial_of_LC9018_plus_doxorubicin_and_doxorubicin_alone_for_the_treatment_of_malignant_pleural_effusion_secondary_to_lung_cancer._The_efficacy_and_safety_of_intrapleural_LC9018_(Yakult_Co._Ltd.,_Tokyo,_Japan)_with_or_without_doxorubicin_(Adriamycin;_Adria_Laboratories,_Columbus,_OH)_were_evaluated_in_a_randomized,_controlled_trial_performed_in_95_patients_with_malignant_pleural_effusions_secondary_to_lung_cancer._Seventy-six_patients_were_eligible_for_the_assessment_of_efficacy._The_response_rate_for_treatment_with_intrapleural_doxorubicin_plus_LC9018_(38_patients)_was_73.7%,_which_was_significantly_higher_than_the_response_rate_of_39.5%_for_the_control_group_treated_with_doxorubicin_alone_(38_patients)_(P_less_than_0.01)._The_LC9018_group_also_showed_a_significantly_greater_improvement_in_performance_status_(PS)_and_symptoms_(chest_pain,_chest_discomfort,_and_anorexia)_than_the_control_group_(P_less_than_0.05)._A_significant_prolongation_of_survival_was_noticed_in_the_LC9018_group_(P_less_than_0.05)._The_main_side_effects_of_LC9018_were_fever_and_transient_hepatic_dysfunction,_but_there_were_no_serious_adverse_reactions._These_results_suggest_that_the_intrapleural_instillation_of_LC9018_can_be_recommended_for_the_treatment_of_malignant_pleural_effusions.